Within a year of reporting preclinical proof of concept for a systemically delivered MPS IIIA gene therapy, Autonomous University of Barcelona researchers have substantially improved efficacy in the CNS while still treating peripheral organs via intracerebral delivery. Partner Esteve is now raising funds to enter the clinic.